23andMe is a leading genetic testing and healthcare company that helps consumers access, understand, and benefit from the human genome. 23andMe offers 3 key products to consumers: “Ancestry Test Kits”, “Ancestry + Genetic Health Test Full Suite Kits” and “23andMe + Total Health”. Through these testing products, customers can receive comprehensive risk assessment reports on their likelihood of developing genetically influenced diseases, including Parkinson’s, Alzheimer’s, Breast Cancer, Ovarian Cancer, Prostate Cancer, diabetes, and a number of other chronic illnesses. Via their Lemonaid Health telehealth platform, they connect patients to licensed healthcare professionals for affordable and direct online medical care. As of October 2023, the Company’s products are offered worldwide, its number of genetic profiles has surpassed 13 million profiles, and is approved to issue more than 55 health reports. 23andMe maintains strategic co-drug development partnerships with large-scale pharmaceutical companies such as GSK. Additionally, 23andMe is currently developing 50 therapeutic programs within its drug pipeline.
